SCHEMBL6818182

SCHEMBL6818182

O=P(Cl)(Cl)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.56
PTGS2 P35354 2/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
SLC6A2 P23975 1/20 0.56
CYP2C19 P33261 1/20 0.56
SLC6A3 Q01959 1/20 0.56
HIF1A Q16665 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
MAOB P27338 4/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
MAOA P21397 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
NR4A1 P22736 1/20 0.54
NR4A2 P43354 1/20 0.54
NR4A3 Q92570 1/20 0.54
BCHE P06276 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800341 0.82 PTGS1 (0.61) PTGS1PTGS2LMNACYP1A2SLC6A2
SCHEMBL339813 0.80 LMNA (0.82) PTGS1PTGS2LMNACYP1A2SLC6A2
SCHEMBL10014793 0.78 LMNA (0.60) PTGS1PTGS2LMNACYP1A2SLC6A2
Benzylphenylether SCHEMBL6286650 0.77 CYP2C19 (0.64) PTGS1PTGS2LMNACYP1A2SLC6A2
Benzylphenylether SCHEMBL18045520 0.77 CYP2C19 (0.64) PTGS1PTGS2LMNACYP1A2SLC6A2
SCHEMBL6794322 0.77 LTA4H (0.67) PTGS1PTGS2LMNACYP1A2SLC6A2
SCHEMBL10014796 0.76 LMNA (0.58) PTGS1PTGS2LMNACYP1A2SLC6A2
SCHEMBL10014794 0.76 LMNA (0.58) PTGS1PTGS2LMNACYP1A2SLC6A2
SCHEMBL10609652 0.76 LMNA (0.75) PTGS1PTGS2LMNACYP1A2SLC6A2
Benzylphenylether SCHEMBL61660 0.76 LMNA (0.74) PTGS1PTGS2LMNACYP1A2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303527-B1 MATRIX METALLOPROTEINASE INHIBITORS LEO PHARMA AS (DK) 2004-09-29 EP disclosed
EP-1303527-A1 MATRIX METALLOPROTEINASE INHIBITORS Leo Pharma A/S (DK) 2003-04-23 EP disclosed
US-6521606-B2 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 2003-02-18 US disclosed
US-20020103166-A1 Matrix metalloproteinase inhibitors LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 2002-08-01 US disclosed
WO-2002006293-A1 MATRIX METALLOPROTEINASE INHIBITORS LEO PHARMA A/S (DK) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103166-A1 Matrix metalloproteinase inhibitors MMP1, MMP9, MMP8 PTGS1 732/4885PTGS2 1556/4885LMNA 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.